论文部分内容阅读
去势抵抗型前列腺癌(CRPC)是指经内分泌治疗产生耐药并继续发展的致命性前列腺癌,雄激素受体(AR)激活途径仍是这一阶段前列腺癌发展的驱动机制,因此抗雄激素治疗仍然是重要的治疗手段之一。虽然许多新型抗雄激素治疗药物在临床治疗中显示了显著的疗效,但同时耐药也频繁出现。《中国肿瘤临床》2015年第20期来自美国俄亥俄州立大学综合癌症中心的王前奔副教授撰写了《抗雄激素药物治疗去势抵抗型前列腺癌的机制
Ovariectomized prostate cancer (CRPC) refers to fatal prostate cancer that is resistant and continues to develop through endocrine therapy. The androgen receptor (AR) activation pathway remains the driving mechanism for the development of prostate cancer during this phase, Hormone therapy is still one of the important treatments. Although many new anti-androgen therapies have shown significant efficacy in clinical treatment, resistance is also frequent. “Cancer Oncology, China” No20-2015 Associate Professor Wang Qianbian from Ohio State University Comprehensive Cancer Center wrote "Mechanism of anti-androgen therapy for castration-resistant prostate cancer